- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, exenatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Artesia, California + 54 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1249–1272
of 7,879
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Saxagliptin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 18,206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 202
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 199 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Trastuzumab emtansine [Kadcyla]
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 40
- States / cities
- Little Rock, Arkansas • Denver, Colorado • Washington D.C., District of Columbia + 34 more
- Conditions
- Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
- Interventions
- Avelumab, Oxaliplatin, 5-Fluorouracil, Leucovorin, Capecitabine, Best supportive care
- Drug · Other
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 35
- States / cities
- Bakersfield, California • Fullerton, California • Los Angeles, California + 31 more
- Conditions
- Central Precocious Puberty
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 3 Years to 9 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Morristown, New Jersey
- Conditions
- Abdominal Aortic Aneurysm
- Interventions
- Decision aid
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- Not listed
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more
- Conditions
- Cryptogenic Sensory Polyneuropathy
- Interventions
- Nortriptyline, Duloxetine, Pregabalin, Mexiletine
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 37 more
- Conditions
- Peanut Allergy
- Interventions
- Dupilumab, Placebo matching dupilumab, AR101
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- insulin degludec, insulin glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- Interventions
- AMG 386, Paclitaxel, AMG 386 Placebo, Carboplatin
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,015 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 173
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 142 more
- Conditions
- Mixed Mesodermal (Mullerian) Tumor, Ovarian Carcinosarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IA Ovarian Cancer AJCC v6 and v7, Stage IA Uterine Sarcoma AJCC v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IB Ovarian Cancer AJCC v6 and v7, Stage IB Uterine Sarcoma AJCC v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage IC Ovarian Cancer AJCC v6 and v7, Stage IC Uterine Sarcoma AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIA Uterine Sarcoma AJCC v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIB Uterine Sarcoma AJCC v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIA Uterine Sarcoma AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIB Uterine Sarcoma AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IIIC Uterine Sarcoma AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Stage IVA Uterine Sarcoma AJCC v7, Stage IVB Uterine Sarcoma AJCC v7, Uterine Carcinosarcoma
- Interventions
- Carboplatin, Ifosfamide, Paclitaxel, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- GOG Foundation
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 637 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 532
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 346 more
- Conditions
- Colorectal Cancer
- Interventions
- leucovorin calcium, tegafur-uracil
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 75 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 49
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 35 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PLN-74809, Placebo
- Drug
- Lead sponsor
- Pliant Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 69 more
- Conditions
- Bronchopulmonary Dysplasia
- Interventions
- Infasurf surfactant (ONY, Inc.), Sham (No Treatment)
- Drug
- Lead sponsor
- Roberta Ballard
- Other
- Eligibility
- 7 Days to 14 Days
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 21
- States / cities
- Little Rock, Arkansas • Berkeley, California • Oakland, California + 15 more
- Conditions
- Opioid-Related Disorders, Heroin Dependence, Morphine Dependence
- Interventions
- Transcranial Direct Current Stimulation (tDCS), Sham Transcranial Direct Current Stimulation (tDCS), Cognitive Training
- Device · Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Malignant Mesothelioma
- Interventions
- capecitabine
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 31 more
- Conditions
- Childhood Obesity
- Interventions
- multi-component/setting parent-targeted intervention
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 2 Years to 4 Years
- Enrollment
- 534 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Migraine
- Interventions
- Ubrogepant 100 mg, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more
- Conditions
- Rheumatic Joint Disease
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 59 more
- Conditions
- Kidney Failure, Surgery, Renal Failure
- Interventions
- Information provision
- Other
- Lead sponsor
- Arbor Research Collaborative for Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Denver, Colorado • Ann Arbor, Michigan + 3 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- givinostat, placebo
- Drug
- Lead sponsor
- Italfarmaco
- Industry
- Eligibility
- 6 Years to 17 Years · Male only
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 13
- States / cities
- Davis, California • San Diego, California • Aurora, Colorado + 10 more
- Conditions
- COPD, Pulmonary Disease, Chronic Obstructive
- Interventions
- Collection of safety data for Cohort 1
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 26
- States / cities
- Anaheim, California • San Diego, California • Bay Pines, Florida + 23 more
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Quemliclustat, Placebo, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 41 more
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
- Interventions
- Carboplatin, Cisplatin, Etoposide, Nivolumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 779
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Anaheim, California + 518 more